Edoxaban, a once daily non-vitamin K antagonist oral anticoagulant, is a direct, selective,
reversible inhibitor of factor Xa (FXa). In healthy subjects, single oral doses of edoxaban …

This is a clinical safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD)
study of a single ascending dose (SAD) and a multiple ascending dose (MAD) of the oral …

Long-term anticoagulation treatment with warfarin has been associated with a number of
limitations in clinical practice and there is a need for more convenient long-term …

This study determined the mass balance and pharmacokinetics of edoxaban in humans after
oral administration of [14C] edoxaban. After oral administration of 60 mg (as active moiety) of …

Background Edoxaban is an oral, once‐daily, direct factor Xa inhibitor under investigation
for stroke prevention in patients with atrial fibrillation and for treatment and secondary …

Edoxaban is an oral direct factor Xa inhibitor that is currently undergoing investigation in
phase III clinical trials for the prevention of stroke in patients with atrial fibrillation (AF) and for …

The primary objective of this study was to assess the effect of a standard high‐fat meal on
the single‐dose (60 mg) pharmacokinetics (PK) of edoxaban in healthy Japanese and …

Edoxaban is an oral factor Xa (FXa) inhibitor in clinical development for stroke prevention in
patients with atrial fibrillation, an elderly population that frequently receives aspirin (ASA) …

Historically, vitamin K antagonists have been the only class of oral anticoagulants available.
Despite our experience with warfarin over the past 60 years, its use is associated with …

Assessment of plasma concentration/effect of edoxaban may be useful in some situations.
Also, clinicians need to know how routine coagulation assays are influenced. It was our aim …